Welcome to our dedicated page for Sol-Gel Technologies Ltd. SEC filings (Ticker: SLGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sol-Gel Technologies Ltd.'s SEC filings document the disclosure record of a foreign private issuer developing and partnering dermatology drug products. Form 6-K reports include operating and financial results, unaudited condensed financial statements, clinical and regulatory updates for SGT-610, SGT-210 and EPSOLAY, and material-event disclosures incorporated by reference into the company's Form S-8 and Form F-3 registration statements.
The filings also cover shareholder meeting materials, auditor appointments, board elections, interim executive leadership approvals under Israeli corporate governance requirements, and capital-structure matters involving the company's ordinary shares. These documents frame Sol-Gel's public-company reporting around dermatology pipeline development, approved topical products, licensing arrangements, governance actions, and financing capacity.
Sol-Gel Technologies Ltd. (SLGL) reported that the last patient has completed the final scheduled visit in its pivotal Phase 3 clinical trial (SGT-610-01) of SGT-610 (patidegib gel, 2%) for prevention of basal cell carcinoma lesions in adults with Gorlin syndrome. This last patient last visit milestone completes the treatment and follow-up phase, after which the company will conduct database lock and statistical analysis, with top-line results expected in late November 2026. The randomized, double-blind, vehicle-controlled study enrolled 113 patients, of whom 102 completed 12 months of twice-daily treatment with either SGT-610 or vehicle, with a primary endpoint of the number of new facial BCCs at month 12 and secondary endpoints including new surgically eligible BCCs.
The company highlights SGT-610 as its lead investigational candidate, described as an orphan- and breakthrough-designated topical hedgehog inhibitor being developed for Gorlin syndrome and potentially high-frequency BCC, alongside its pipeline candidate SGT-210 and its two FDA-approved dermatology products TWYNEO and EPSOLAY.
Sol-Gel Technologies Ltd. (SLGL) reports that Opaleye Management Inc., a ten percent owner, indirectly purchased 3,124 ordinary shares in open-market transactions on September 10–11, 2026 through Opaleye, L.P. A separately managed account for which Opaleye Management acts as portfolio manager held 15,000 ordinary shares as of September 10, 2026. Opaleye Management may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Sol-Gel Technologies Ltd. (SLGL) reports that Opaleye Management Inc., a ten percent owner, indirectly purchased additional ordinary shares over several days in September 2026. Through Opaleye, L.P., it bought a total of 9,976 ordinary shares between September 4 and September 9, 2026 at prices generally around $68–$70 per share, including weighted-average purchases with disclosed price ranges. Opaleye Management Inc. reports these positions as indirectly held and disclaims beneficial ownership beyond its pecuniary interest, and no Rule 10b5-1 trading plan is reported.
Sol-Gel Technologies Ltd. (SLGL) had insider activity reported by Opaleye Management Inc., a more-than-10% owner. On September 1–2, 2026, entities it manages purchased 1,683 ordinary shares of Sol-Gel in open-market or private transactions at prices around $68.94–$69.52 per share, held indirectly through a fund and a managed account. A managed account associated with Opaleye Management Inc. held 15,000 ordinary shares after these transactions. No Rule 10b5-1 trading plan is reported, and Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest.
Sol-Gel Technologies Ltd. (SLGL) reports that large shareholder Opaleye Management Inc. filed a Form 4 showing open-market purchases of 40,330 ordinary shares on August 28 and 31, 2026. The shares were acquired indirectly through Opaleye, L.P. and a separately managed account, with 15,000 shares reported as held in the managed account. Certain trades used weighted average prices within disclosed ranges, and Opaleye Management Inc. disclaims beneficial ownership except to the extent of its pecuniary interest.
Sol-Gel Technologies Ltd. (SLGL) reported a sharp year-over-year decline in revenue and a swing to loss for the quarter ended June 30, 2026, while emphasizing progress in its late-stage dermatology pipeline. Second-quarter 2026 revenue was $0.6 million, down from $17.3 million a year earlier, mainly because the 2025 period included $16.7 million from a one-time sale of IP under the Mayne agreement.
Research and development expenses fell to $3.7 million from $4.6 million, and general and administrative expenses declined to $1.0 million from $1.4 million. The company posted a net loss of $3.7 million (loss of $1.13 per share), versus net income of $11.6 million ($4.17 per share) in the prior-year quarter. As of June 30, 2026, Sol-Gel held $18.0 million in cash, cash equivalents and deposits and $31.3 million in marketable securities, totaling $49.3 million, and expects these resources to fund operations into the first quarter of 2028.
The company highlighted continued advancement of its pivotal Phase 3 trial of SGT-610 (patidegib gel, 2%) in Gorlin syndrome, with last patient last visit expected in September 2026 and top-line data anticipated in late November 2026. Additional studies are underway in high-frequency basal cell carcinoma and as a neo-adjuvant treatment in BCC surgery, and Sol-Gel filed a provisional patent for an intra-cystic injectable hedgehog inhibitor for odontogenic keratocysts.
Opaleye Management Inc., a more than ten percent owner of Sol-Gel Technologies Ltd., reported an indirect open-market purchase of 951 Ordinary Shares on 2026-08-12 at $71.50 per share, held via Opaleye, L.P. Following this trade, that fund’s indirect holdings in Sol-Gel total 494,887 Ordinary Shares. A separate line reports 15,000 Ordinary Shares held in a managed account. Opaleye Management Inc. states that it may be deemed to beneficially own these securities through its roles with the fund and managed account, but disclaims beneficial ownership except to the extent of its pecuniary interest.
Opaleye Management Inc., a ten percent owner of Sol-Gel Technologies Ltd., reported net insider buying. Through Opaleye, L.P., it purchased 775 ordinary shares on July 13 and 920 shares on July 14, 2026, in open‑market transactions at weighted‑average prices of $73.89 and $73.43 per share, executed in multiple trades within disclosed ranges of $73.34–$73.50 and $73.75–$73.95. Following these trades, Opaleye, L.P. holds 493,936 shares, and a separately managed account overseen by Opaleye Management holds 15,000 shares. Opaleye Management disclaims beneficial ownership beyond its pecuniary interest.
Opaleye Management Inc., a more than ten percent owner of Sol-Gel Technologies Ltd., reported open-market purchases of the company’s ordinary shares. On July 8, 2026, an affiliated fund bought 300 shares at $73.69 per share, and on July 10, 2026 it bought an additional 229 shares at $73.95 per share. After these trades, the fund held 492,241 shares indirectly attributed to Opaleye Management Inc., and a separately managed account associated with it held 15,000 shares, with Opaleye Management Inc. disclaiming beneficial ownership beyond its pecuniary interest.
Opaleye Management Inc., a more than ten percent owner of Sol-Gel Technologies Ltd., reported additional indirect purchases of the company’s ordinary shares. Through Opaleye, L.P., it completed open-market purchases totaling 1,712 shares at prices ranging from $71.96 to $71.99 per share. After these trades, Opaleye, L.P. held 491,712 ordinary shares, while a separately managed account overseen by Opaleye Management held 15,000 shares, both positions being reported as indirect holdings. Opaleye Management disclaims beneficial ownership of these shares beyond any pecuniary interest.